Effects and patient compliance of sustained-release versus immediate-release glipizides in patients with type 2 diabetes mellitus: A systematic review and meta-analysis

Journal of Evidence-Based Medicine

Volumn 4, Issue 4, 2011, Pages 232-241

  Wang, Li ^a   Sun, Xin ^a,b   Du, Liang ^a   Yuan, Qiang ^a   Li, Honghao ^a   Tian, Haoming ^a   Li, Youping ^a  

^a SICHUAN UNIVERSITY   (China)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

Glipizide; Meta analysis; Type 2 diabetes mellitus

Indexed keywords

GLIPIZIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN;

BLOOD GLUCOSE MONITORING; CLINICAL ASSESSMENT; CLINICAL TRIAL; COCHRANE LIBRARY; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DATA EXTRACTION; DIABETIC PATIENT; DIARRHEA; DRUG DOSE TITRATION; DRUG EFFECT; DRUG INDUSTRY; EMBASE; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RELEASE; MAJOR CLINICAL STUDY; MEDLINE; META ANALYSIS; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; REVIEW; RISK; SCREENING; SUSTAINED DRUG RELEASE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VOMITING;

BLOOD GLUCOSE; DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS, TYPE 2; GLIPIZIDE; HUMANS; HYPOGLYCEMIC AGENTS; MEDICATION ADHERENCE;

EID: 82455167050     PISSN: 17565383     EISSN: 17565391     Source Type: Journal    
DOI: 10.1111/j.1756-5391.2011.01158.x     Document Type: Review

References (42)

1. IDF Clinical Guidelines Task Force. Global guideline for Type 2 diabetes. Brussels: International Diabetes Federation, 2005.
2. International Diabetes Federation. IDF DIABETES ATLAS. 4th ed. 2009. Retrieved from:
3. Fertig BJ, Simmons DA, Martin DB. Therapy for diabetes. In: National Diabetes data Group, ed. Diabetes in America. 2nd ed. Wahingtong DC: US Govt Printing Office, 1995: 95-1468.
4. Lebovitz HE. Glipizide: a second-generation sulfonylurea hypoglycemic agent: pharmacology, pharmacokinetics and clinical use. Pharmacotherapy 1985; 5(2): 63-77.
5. Simonson DC, Kourides IA, Feinglos M, Shamoon H, Fischette CT. Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastrointestinal Therapeutic System Study Group. Diabetes Care 1997; 20(4): 597-606.
6. Cefalu WT, Bell-Farrow A, Wang ZQ, Mcbride D, Dalgleish D, Terry JG. Effect of glipizide GITS on insulin sensitivity, glycemic indices, and abdominal lipid composition in NIDDM. Drug Develop Res 1998; 44(1): 1-7.
7. Go EH, Kyriakidou-Himonas M, Berelowitz M. Effects of glipizide GITS and glibenclamide on metabolic control, hepatic glucose production, and insulin secretion in patients with type 2 diabetes. Diabetes Metab Res Rev 2004; 20(3): 225-31.
8. Feinglos M, Dailey G, Cefalu W, Osei K, Tayek J, Canovatchel W, et al Effect on glycemic control of the addition of 2.5 mg glipizide GITS to metformin in patients with T2DM. Diabetes Res Clin Pract 2005; 68(2): 167-75.
9. Berelowitz M, Fischette C, Cefalu W, Schade DS, Sutfin T, Kourides IA. Comparative efficacy of a once-daily controlled-release formulation of glipizide and immediate-release glipizide in patients with NIDDM. Diabetes Care 1994; 17(12): 1460-4.
10. Chung M, Kourides I, Canovatchel W, Sutfin T, Messig M, Chaiken RL. Pharmacokinetics and pharmacodynamics of extended-release glipizide GITS compared with immediate-release glipizide in patients with type II diabetes mellitus. J Clin Pharmacol 2002; 42(6): 651-7.
11. Cerkoney KA, Hart LK. The relationship between the health belief model and compliance of persons with diabetes mellitus. Diabetes Care 1980; 3: 594-8.
12. World Health Organization. Adherence to Long-term Therapies. Evidence for Action. Geneva: World Health Organization, 2003
13. Van Larr FA, Lucassen PLBJ, Akkermans RP. Alpha-glucosidase inhibitors for type 2 diabetes mellitus: a systematic review. Chinese Journal of Evidence-based Medicine 2006; 6(5): 335-51.
14. Wells GA, Shea B, O'Connell D. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2009. Retrieved from:
15. Egger M, Davey Smith G, Altman DG. Systematic reviews in health care: meta-analysis in context. 2nd ed. London: BMJ Books, 2001.
16. Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ 2003; 326: 219.
17. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088-101.
18. Zhang X. The effect of extended-release glipizide for type 2 diabetes mellitus. Fujian Medical Journal 2000; 22(3): 23-4. (In Chinese)
19. Wang P, Yao C, Wang W. The comparison of efficacy between glipizide GITS and GIR for type 2 diabetes mellitus. China pharmacy 2001; 12(4): 230. (In Chinese)
20. Zeng W, Shen H. The extended-release glipizide for type 2 diabetes mellitus. Journal of Shanghai Second Medical University 2001; 21(1): 84-5. (In Chinese)
21. Chen B, Cai H, Luo M. Randomized clinical trial of Glucotrol XL, a release-controlled glipizide, in treatment for type 2 diabetes. Acta Acadimiae Medicinae Militaris Tertiae 2003; 25(2): 164-5. (In Chinese)
22. Guo X, Huang Y, Liang D. Clinical effects of glipizide gastrointestinal therapeutic system in treatment of secondary failure to sulfonylurea in noninsulin dependent diabetes mellitus. Chinese Journal of Clinical Pharmacy 2004; 13(3): 139-41. (In Chinese)
23. Li C, Xue Y, Gao F. The effects on the secretion of islet and sensitivity of insulin of sustained-release glipizide for type 2 diabetes mellitus. Guangdong Medical Journal 2004; 25(6): 719-20. (In Chinese)
24. Shen L, Chen K, Xie Y. Sustained-release glipizide for the treatment of type 2 diabetes mellitus among 30 patients. Herald of Medicine 2004; 23(11): 828-9. (In Chinese)
25. Ji L. The Clinical effects of extended-release glipizide for type 2 diabetes mellitus. Modern practical Medicine 2005; 17(8): 492-3. (In Chinese)
26. Wang J, Jiang L, Cai J. The pharmacoeconomic study of different forms of glipizide for type 2 diabetes mellitus. Chinese Journal of Hospital Pharmacy 2005; 25(9): 866-7. (In Chinese)
27. Yang X. Influence of blood glucose and blood lipid of dyslipidosis associated with type 2 diabetes mellitus patients with glipizide GITS. Chinese General Practice 2005; 8(4): 279-80. (In Chinese)
28. Hsieh SH, Lin JD, Cheng HY, Ho C, Liou MJ. Sustained-release versus immediate-release glipizide for treatment of type 2 diabetes mellitus in Chinese patients: A randomized, double-blind, double-dummy, parallel-group, 12-week clinical study. Clin Ther 2006; 28(9): 1318-26.
29. Yao M, Shang Y, Xu Q. The effects on sensitivity to insuline of glipizide XL for type 2 diabetes. Sichuan Medical Journal 2006; 27(7): 713-4. (In Chinese)
30. Zhao X, Zhou Y, Yang J. Clinical study of controlled-release formula of glipizide in the treatment of coronary artery disease complicated with type 2 diabetes mellitus. Journal of Capital University of Medical Sciences 2006; 27(1): 78-80. (In Chinese)
31. Wu Y. the comparison of efficacy between glipizide GITS and immediate-release among the old patients with type 2 diabetes mellitus. Journal of Practical Diagnosis and Therapy 2007; 21(2): 135. (In Chinese)
32. Zhang W, Wu H. the efficacy between glipizide GITS and glipizide for type 2 diabetes mellitus. Chinese Community Doctors 2007; 21(5): 26. (In Chinese)
33. Cai M, Yang S, Qi Y. the comparison of efficacy between glipizide GITS and immediate-release glipizide for type 2 diabetes mellitus. Chongqing Medical Journal 2008; 29(5): 529-30. (In Chinese)
34. Deng LY. Glipizide GITS and immediate-release glipizide in treatment of type 2 diabetes mellitus. China Modern Medicine 2010; 17(21): 73-4. (In Chinese)
35. Yao P, Zhao LX, Wang Z. The clinical study on treating type 2 diabetes mellitus with glipizide. Clinical Journal of Chinese Medicine 2010; 2(18): 26-7. (In Chinese)
36. Zhang HF, Qi JH. Efficacy and safety of sustained-release glipizide for type 2 diabetes mellitus. China Practical Medicine 2011; 6(5): 163-4. (In Chinese)
37. Dezii CM, Kawabata H, Tran M. Effects of once-daily and twice-daily dosing on adherence with prescribed glipizide oral therapy for type 2 diabetes. South Med J 2002; 95(1): 68-71.
38. Harley CR, Mishra A, Cantor SE, Nelson M, Walker AM. A 'real-world' analysis of persistence on and adherence to glipizide GITS, glipizide IR and glibenclamide in managed care among patients with type 2 diabetes mellitus. Clin Drug Invest 2002; 22(9): 575-84.
39. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications - report of a WHO consultation. Part 1: diagnosis and classification of diabetes mellitus. WHO/NCD/NCS/99.2. Geneva: World Health Organization, 1999.
40. Gavin JR, Alberti KGMM, Davidson MB. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20: 1183-97.
41. World Health Organization. Diabetes Mellitus: Report of a WHO Study Group. Technical Report Series No. 727. Geneva: World Health Organization, 1985.
42. Kelly TN, Bazzano LA, Fonseca VA, Thethi TK, Reynolds K, He J. Systematic review: glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med 2009; 151: 394-403.